- Home
- FENC vs MRCC Comparison
FENC vs MRCC Comparison
Compare FENC & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FENC
- MRCC
- Stock Information
- Founded
- FENC 1996
- MRCC 2011
- Country
- FENC United States
- MRCC United States
- Employees
- FENC N/A
- MRCC N/A
- Industry
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- MRCC Investment Managers
- Sector
- FENC Health Care
- MRCC Finance
- Exchange
- FENC Nasdaq
- MRCC Nasdaq
- Market Cap
- FENC 156.9M
- MRCC 176.4M
- IPO Year
- FENC 2001
- MRCC 2012
- Fundamental
- Price
- FENC $5.08
- MRCC $7.18
- Analyst Decision
- FENC Strong Buy
- MRCC Hold
- Analyst Count
- FENC 2
- MRCC 1
- Target Price
- FENC $14.00
- MRCC $8.00
- AVG Volume (30 Days)
- FENC 87.7K
- MRCC 87.7K
- Earning Date
- FENC 05-13-2025
- MRCC 05-07-2025
- Dividend Yield
- FENC N/A
- MRCC 14.10%
- EPS Growth
- FENC N/A
- MRCC 2515.72
- EPS
- FENC N/A
- MRCC 0.45
- Revenue
- FENC $47,538,000.00
- MRCC $60,527,000.00
- Revenue This Year
- FENC $2.68
- MRCC N/A
- Revenue Next Year
- FENC $71.63
- MRCC N/A
- P/E Ratio
- FENC N/A
- MRCC $16.03
- Revenue Growth
- FENC 123.69
- MRCC N/A
- 52 Week Low
- FENC $3.96
- MRCC $6.55
- 52 Week High
- FENC $10.07
- MRCC $8.85
- Technical
- Relative Strength Index (RSI)
- FENC 34.36
- MRCC 43.05
- Support Level
- FENC $5.02
- MRCC $6.75
- Resistance Level
- FENC $5.50
- MRCC $7.27
- Average True Range (ATR)
- FENC 0.41
- MRCC 0.34
- MACD
- FENC -0.03
- MRCC 0.02
- Stochastic Oscillator
- FENC 22.22
- MRCC 45.95
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About MRCC Monroe Capital Corporation
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.